Previously developed murine monoclonal antibodies (MAbs) to human β2-glycoprotein I (β2GPI), a plasma protein required for the binding of anti-phospholipid antibodies, were studied for anti-platelet reactivity and influence on platelet function. The six MAbs (IgG1 isotype) tested interacted with both intact and fixed platelets in a β2GPI-dependent manner. Carbamylated β2GPI was still recognized by MAbs but was unable to mediate platelet- antibody binding. MAbs induced aggregation and secretion responses of platelets in platelet-rich plasma (PRP) and whole blood, provided subthreshold concentrations of weak agonists (i.e. ADP or adrenaline) were added. When aggregation in PRP was evaluated by a counting technique instead of turbidometrically, the sole addition of MAbs led to a rapid fall in single platelets. Triggering gel-filtered platelets with MAbs together with β2GPI, but not its carbamylated form, led to platelet activation after a lag time, as monitored by aggregometry, measurements of ATP and β-thromboglobulin secretion and calcium mobilization. F(ab')2 fragments of one of the MAbs failed to activate platelets but inhibited the responses to the whole antibody. This process thus depends on MAbs binding to platelets through both Fab and Fc domains, as confirmed by the suppression of platelet responses upon pretreatment with the anti-FcγRII MAb IV.3. Aggregation and secretion induced by MAbs plus β2GPI did not require exogenous fibrinogen and were variably inhibited in the presence of acetyl salicylic acid, apyrase or Ca2+, depending on the concentrations used for the two proteins. We propose that platelet FcγRII crosslinking that follows a platelet-antibody interaction via the platelet binding protein, β2GPI, may be a new mechanism by which anti-β2 GPI antibodies activate platelets and/or synergize with weak agonists.
References
1
McNeil NP,
Chesterman CN,
Krillis SA.
Immunology and clinical importance of anti-phospholipid antibodies. Adv Immunol 1991; 49: 193-280
4
Schousboe I.
Characterization of the interaction between β2-glycoprotein I and mitochondria, platelets, liposomes and bile acids. Int J Biochem 1983; 15: 1393-1401
5
Nimpf J,
Wurm H,
Kostner GM.
Interaction of β2-glycoprotein I with human blood platelets: influence upon the ADP-induced aggregation. Thromb Haemostas 1985; 54: 397-401
6
McNeil HP,
Simpson RJ,
Chesterman CN,
Krillis SA.
Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H). Proc Natl Acad Sci 1990; 87: 4120-4124
7
Oosting JD,
Derksen RHWM,
Entjes HTI,
Bouma BN,
de Groot PG.
Lupus anticoagulant activity is frequently dependent on the presence of β2-glycoprotein I. Thromb Haemostas 1992; 67: 499-502
9
Nimpf J,
Bevers EM,
Bomans PHH,
Till U,
Wurm H,
Kostner GM,
Zwaal RFA.
Prothrombinase activity of human platelets is inhibited by β2-glycoprotein I. Biochim Biophys Acta 1986; 884: 142-149
10
Nimpf J,
Wurm H,
Kostner GM.
β2-glycoprotein I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 1987; 63: 109-114
12
Arvieux J,
Roussel B,
Jacob MC,
Colomb MG.
Measurement of antiphospholipid antibodies by ELISA using β2-glycoprotein I as an antigen. J Immunol Meth 1991; 143: 223-229
13
Means GE,
Feeney RE.
In: Chemical modification of proteins. Holden-Day Inc; San Franciso, CA: 1971: 215-216
14
Frojmovic MM,
Milton JG,
Duchastel A.
Microscopic measurements of platelet aggregation reveal a low ADP-dependent process distinct from turbidometrically measured aggregation. J Lab Clin Med 1983; 101: 964-976
15
Grynkiewicz G,
Poenie M,
Tsien RV.
A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 1985; 260: 3440-3450
18
Worthington RE,
Carroll RC,
Boucheix C.
Platelet activation by CD9 monoclonal antibodies is mediated by the FcϒII receptor. Br J Haematol 1990; 74: 216-222
19
Slupsky JR,
Cawley JC,
Griffith LS,
Shaw ARE,
Zuzel M.
Role of FcϒRII in platelet activation by monoclonal antibodies. J Immunol 1992; 148: 3189-3194
22
Packham MA,
Kinlough-Rathbone RL,
Mustard JF.
Thromboxane A2 causes feedback amplification involving extensive thromboxane A2 formation on close contact of human platelets in media with a low concentration of ionized calcium. Blood 1987; 70: 647-651
24
Pfueller SL,
Weber S,
Lusher EF.
Studies on the mechanism of the human platelet release reaction induced by immunologic stimuli. III. Relationship between the binding of soluble IgG aggregates to the Fc receptor and cell response in the presence and absence of plasma. J Immunol 1977; 109: 514-524
25
Pfueller SL,
David R.
Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haematol 1986; 64: 149-159
28
Escolar G,
Font J,
Reverter JC,
Lopez-Soto A,
Garrido M,
Cervera R,
Ingelmo M,
Castillo R,
Ordinas A.
Plasma from systemic lupus erythematosus patients with anti-phospholipid antibodies promotes platelet aggregation – Studies in a perfusion system. Arterioscler Thromb 1992; 12: 196-200
30
Out HJ,
de Groot PG,
van Vliet M,
de Gast GC,
Nieuwenhuis HK,
Derksen RHWM.
Antibodies to platelets in patients with antiphospholipid antibodies. Blood 1991; 77: 2655-2659
